Drugs / CHO-H01
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03221348 | Mar 2018 → Oct 2019 | follicular lymphoma | Cho Pharma Inc. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05950165 | Jan 2020 → Dec 2026 expected | non-Hodgkin lymphoma | Cho Pharma Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CHO-H01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05950165 ↗ |
| Modality | Monoclonal antibody | “Glyco-engineered anti-CD20 antibody” NCT03221348 ↗ |
| Route | Intravenous | “CHO-H01 Administered Intravenously” NCT03221348 ↗ |